Breast cancer is world’s most studied disease, report finds
Breast cancer is the most studied disease globally for a fifth year running, a new report reveals.
Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes, prostate cancer and non-small cell lung cancer (NSCLC).
According to the analysis, the US led global clinical trial activity in 2025 across the top five indications. China recorded the fastest growth in the number of recruiting clinical trial sites, registering a 51% increase in trial sites between 2023 and 2025 compared to 42% in the US. China also ranked second in research for all diseases in the top five except for prostate cancer.
Elsewhere, Canada ranked second for studies into prostate cancer, while France, Italy and Spain made the top five countries for recruiting investigator sites.
“Breast cancer continues to dominate because researchers have a far deeper understanding of its biomarkers,” said Dr Gen Li, Founder and President of Phesi.
“There are still many unmet needs to be addressed, such as in triple negative breast cancer, but sustained clinical research investment in this devastating disease is encouraging.”
Trial termination rate “unacceptably high”
Analysis by Phesi found that just 26% of Phase II trials were terminated early in 2025, a four-year low. The figures indicate an improvement on data showing 31% of Phase II trials were terminated in 2024, up from 29% in 2023 and around 20% before Covid-19.
However, Li argued the termination rate was still “unacceptably high”.
“Sponsors remain under pressure from macroeconomic constraints, pricing challenges and increased activity in regions such as China.” Li said. “We are also seeing the effect of renewed emphasis from regulators, including the FDA, on country-specific representation. Well-known and high-profile investigator sites are quickly saturated as sponsors seek them out.
“However, there is considerable opportunity to identify investigator sites elsewhere that may have a shorter clinical trial and enrolment history, but have capacity and have delivered high quality data in previous trials.
“The increase in competition, regulatory changes and acceptance of digital patient data mean it is vital for sponsors to be led by insight informed by big data and AI, rather than instinct. Considerable volumes of contextualised and real-world data exist to power clinical data analytics that overcome these hurdles.”
Analysts predict surge in obesity studies
Obesity remained just outside the top five most studied diseases, ranking sixth in 2025.
A separate Phesi analysis in September 2025 showed that more than 100 diseases are being investigated in connection with GLP-1 use, reflecting growing interest in obesity as a comorbidity in a wide range of diseases. This increase suggests obesity is the disease area most likely to enter the top five within the next one to two years.
“Although the pandemic is still having lingering effects as a disruptor, sponsors should now be looking ahead to what the next disruptor might be,” Li added.
“The broader adoption of GLP-1s, for example, could reshape the clinical development landscape as the focus shifts towards prevention and treating clusters of related disease.”
Bruno Quinney, Content Team, DDW
